Haag-Streit UK is pleased to announce the appointment of Thomas Lenzen as the new Chief Executive Officer (CEO) of the Haag-Streit Group.
Thomas Lenzen.
With more than two decades of international leadership experience in the med tech industry, Thomas Lenzen brings deep expertise in ophthalmology and a proven track record of driving business growth. He previously held senior leadership and management roles at Bausch + Lomb. Most recently, he was Vice President International at Haemonetics, overseeing the company’s international operations for the business unit plasma and blood centre.
Commenting on his appointment, Thomas Lenzen said: “Haag-Streit has a remarkable history of shaping ophthalmology through pioneering solutions and a strong commitment to precision and quality. I am honoured to lead the company into its next phase of growth. Together with my new colleagues around the world, I look forward to building on the strength of the current portfolio and driving our strategy forward with energy, innovation, and passion.”
FURTHER INFORMATION:
T: +44 (0) 1279 883829
E: info.unitedkingdom@haag-streit.com
W: www.haagstreituk.com
